The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.

Emerging data suggest that treatment outcomes with aromatase inhibitors (AIs) and/or tamoxifen may differ for tumors that express both the estrogen receptor (ER) and the progesterone receptor (PR) (ER+/PR+) compared with those that lack PR expression (ER+/PR-). However, the optimal sequencing of AIs and tamoxifen as adjuvant therapy is not known and may differ for biologic subsets of cancers. Markov models were used to simulate disease-free survival (DFS) separately among postmenopausal women with ER+/PR+ cancers and women with ER+/PR- cancers. By using risk estimates reported from randomized clinical trials, treatment with 5 years of an AI alone with sequential treatment consisting of tamoxifen with crossover to an AI at 2 years was compared. For women with ER+/PR+ cancers, sequential therapy with tamoxifen followed by crossover to an AI at 2 years yielded modest improvements in 10-year DFS estimates compared with planned AI monotherapy (84.3% vs. 82.2% and 68.8% vs. 64.8% for lymph node-negative and lymph node-positive patients, respectively). However, for women with ER+/PR- cancers, upfront treatment with an AI yielded improved outcomes with 10-year DFS rates of 90.5% and 80.1% for the lymph node-negative and node-positive groups, respectively, compared with 88.2% and 76.1%, respectively, for sequential treatment with tamoxifen followed by an AI. Modeling estimates suggested that the optimal endocrine treatment strategy may differ based on the biologic features of breast cancer tumors. Patients with ER+/PR+ tumors achieved optimal 10-year DFS estimates with tamoxifen followed by a crossover to AI therapy, whereas patients with ER+/PR- tumors fared best when they initiated treatment with AI.

Punglia RS ，Kuntz KM ，Winer EP ，Weeks JC ，Burstein HJ ... -  《CANCER》

Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.

Punglia RS ，Kuntz KM ，Winer EP ，Weeks JC ，Burstein HJ ... -  《JOURNAL OF CLINICAL ONCOLOGY》

Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.

Arpino G ，Weiss H ，Lee AV ，Schiff R ，De Placido S ，Osborne CK ，Elledge RM ... -  《-》

Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.

Viale G ，Regan MM ，Maiorano E ，Mastropasqua MG ，Golouh R ，Perin T ，Brown RW ，Kovács A ，Pillay K ，Ohlschlegel C ，Braye S ，Grigolato P ，Rusca T ，Gelber RD ，Castiglione-Gertsch M ，Price KN ，Goldhirsch A ，Gusterson BA ，Coates AS ... -  《-》

Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.

Ellis MJ ，Tao Y ，Luo J ，A'Hern R ，Evans DB ，Bhatnagar AS ，Chaudri Ross HA ，von Kameke A ，Miller WR ，Smith I ，Eiermann W ，Dowsett M ... -  《-》